Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Rhea-AI Summary

Synlogic, Inc. (Nasdaq: SYBX) announced its participation at the SIMD 44^th Annual Meeting in Salt Lake City on March 19, 2023. The company will present a podium presentation on Phase 2 data for its PKU treatment, SYNB1618 and SYNB1934, led by Dr. Jerry Vockley. Additionally, two poster presentations will showcase findings on SYNB1353 for homocystinuria. The presentations underscore Synlogic's commitment to developing innovative therapies for inborn metabolic disorders. Dr. Dave Hava expressed enthusiasm for sharing new data that may alleviate burdens faced by patients and caregivers.

– Podium presentation on Phase 2 phenylketonuria (PKU) data –

– Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data –

CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that it will present a podium presentation and two poster presentations at the Society for Inherited Metabolic Disorders (SIMD) 44^th Annual Meeting in Salt Lake City, Utah on March 19, 2023.

• Podium Presentation: Synpheny-1: A Phase 2 Study of the Efficacy and Safety of SYNB1618 and SYNB1934 in Patients with Phenylketonuria
• Presenting author: Dr. Jerry Vockley, MD, PhD, Director, Center for Rare Disease Therapy, Chief, Medical Genetics at UPMC Children’s Hospital of Pittsburgh, Professor of Pediatrics and Human Genetics at University of Pittsburgh and lead investigator of Synlogic’s PKU Phase 2 Synpheny-1 study
• Date and time: Sunday, March 19, 2023 at 4:15 p.m. MT (6:15 p.m. ET)
  
  

• Poster Presentation #119: SYNB1353, A Proposed Therapy for Homocystinuria, Lowers Plasma Methionine and Homocysteine in Healthy Volunteers Exposed to a Methionine Challenge
• Presenting author: Dr. Neal Sondheimer, Medical Director, Synlogic
• Date and time: Sunday, March 19, 2023 at 8 p.m. MT (10 p.m. ET)
  
  

• Poster Presentation #95: Gastrointestinal Methionine Metabolism with Live Biotherapeutics SYNB1353 Results in Improved Plasmas Methionine and Homocysteine Levels in Mice and Nonhuman Primates
• Presenting author: Dr. Mylene Perreault, Vice President, Nonclinical Development and Biology, Synlogic
• Date and time: Sunday, March 19, 2023 at 8 p.m. MT (10p.m. ET)
  

“We are delighted to have the opportunity to present further data for both the PKU and HCU programs at SIMD, with the leading experts in inborn errors of metabolism,” said Dr. Dave Hava, Chief Scientific Officer and Head of Research and Development at Synlogic. "We recognize that PKU and HCU continue to cause tremendous burden to patients and caregivers, and we look forward to sharing data from these programs with the expert clinicians at this congress.”

Following the presentations, all abstracts will be posted to the Publications page of the Synlogic website.

About Synlogic

Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases. In addition to its clinical programs, Synlogic has a research collaboration with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease or IBD. Synlogic has also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout. For additional information visit www.synlogictx.com. 

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," “look forward,” "estimate," "expect," "intend," on track,” "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of SYNB1934, SYNB1353, SYNB8802 and SYNB2081 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

Media Contact: media@synlogictx.com

Investor Relations: investor@synlogictx.com

FAQ

What will Synlogic present at the SIMD Annual Meeting on March 19, 2023?

Synlogic will present a podium presentation on Phase 2 data for SYNB1618 and SYNB1934 in patients with phenylketonuria, along with two poster presentations on SYNB1353's effects in homocystinuria.

Who is leading the podium presentation for Synlogic's PKU study?

Dr. Jerry Vockley, a prominent medical expert, will lead the podium presentation on the Phase 2 study of SYNB1618 and SYNB1934.

What are the key findings of Synlogic's presentations on March 19, 2023?

Synlogic's presentations will highlight new data regarding the efficacy and safety of its treatments for phenylketonuria and homocystinuria.

When and where is Synlogic's presentation at the SIMD meeting?

Synlogic's podium presentation is scheduled for March 19, 2023, at 4:15 p.m. MT (6:15 p.m. ET) in Salt Lake City, Utah.

What is the significance of SYNB1353 in Synlogic's HCU research?

SYNB1353 aims to treat homocystinuria by lowering plasma methionine and homocysteine levels, demonstrating significant potential in the ongoing clinical studies.